- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$2.50 BnMarket Estimate, 2026
$2.67 BnMarket Forecast, 2034
$4.55 BnCAGR, 2026–2034
6.9%North America HPV Testing and Pap Test Market Size, Growth, Trends & Forecast (2026–2034)
The North America HPV Testing and Pap Test market size was valued at USD 2.50 billion in 2025, is anticipated to reach USD 2.67 billion in 2026, and is projected to scale up to USD 4.55 billion by 2034, registering a compound annual growth rate (CAGR) of 6.9% during the forecast period from 2026 to 2034. Market expansion is primarily propelled by the soaring prevalence of cervical cancer, high baseline HPV infection rates, government-backed early screening awareness campaigns, and continuous technological enhancements in molecular diagnostics.
Key Executive Metrics (At-a-Glance)
- 2025 Base Valuation: USD 2.50 Billion
- 2026 Current Valuation: USD 2.67 Billion
- 2034 Forecast Valuation: USD 4.55 Billion
- Compound Annual Growth Rate (CAGR): 6.90% (2026–2034)
- Dominant Test Type Segment: HPV Testing (including HPV Primary Testing and Co-Testing) and Traditional Pap Tests
- Dominant Application Segment: Cervical Cancer Screening
- Dominant End-User Segment: Laboratories, Hospitals, and Physician Offices/Clinics
- Regional Growth Leaders: The United States (commanding the largest regional share) followed by Canada.
Core Market Drivers
- High Incidence of Cervical Cancer & HPV: Millions of newly tracked HPV infections annually across North America fueling routine clinical screening demand.
- Healthcare Infrastructure & Expenditure: Rising per-capita healthcare spending and favorable health policies in the United States and Canada stimulating diagnostic adoption.
- Government & Institutional Awareness Programs: Public health initiatives aimed at early cervical cancer diagnosis and timely treatment intervention.
Primary Market Restraints & Challenges
- Diagnostic Limitations: Inability of certain standard microscopic observation tests to capture all high-risk genotypes, alongside potential false-negative results.
- Procedural Inconsistencies: Evolving screening guidelines across different jurisdictions that can create occasional tracking and diagnostic friction.
North America HPV Testing and Pap Test Market Segmentation Breakdown
| Segment Category | Key Offerings / Categories |
|---|---|
| By Test Type | HPV Testing (Follow-up HPV Testing, HPV Primary Testing, Co-Testing), PAP Test |
| By Application | Cervical Cancer Screening, Vaginal Cancer Screening |
| By End-Users | Laboratories, Hospitals, Physicians Offices and Clinics |
| By Country | The United States, Canada, Rest of North America |
Major Industry Players Profiled
Key companies dominating the North America HPV Testing and Pap Test market include Abbott Laboratories, Qiagen N.V., Roche Diagnostics, Hologic, Inc., Becton, Dickinson and Company, Quest Diagnostics, Onco Health Corporation, Seegene, Inc., Femasys Inc., and Arbor Vita Corporation.
North America HPV Testing and Pap Test Market Size
The North America HPV Testing and Pap Test market size was valued at USD 2.50 billion in 2025 and is anticipated to reach USD 2.67 billion in 2026 from USD 4.55 billion by 2034, growing at a CAGR of 6.9% during the forecast period from 2026 to 2034.
According to the WHO, cervical cancer is the fourth most common cancer in women. An estimated 6,28,924 new cases of the cervix were diagnosed in 2020, so the growing number of patients will drive overall market growth. The Centers for Disease Control (CDC) predicts that approximately 78 million people are currently infected with HPV in the United States, and it is about 14 million people in the United States are infected with new HPV infections each year. Therefore, the increasing number of cervical cancer cases has driven the market demand for HPV and Pap tests.
These tests include the microscopic observation of the samples. However, these tests cannot detect all of the genotypes that cause HPV infections and can also lead to a significant number of false negatives.
Regionally, in 2024, North America commanded the market in terms of revenue because of the continual introduction of innovative technologies to improve patient care and diagnosis. Additionally, the high number of positive cases being detected, coupled with the increasing death toll (i.e., 2.6 in 1,00,000), has forced the government to carry out awareness programs regarding the early diagnosis and treatment of cervical cancer, which is a significant factor for the large market share.
About 2.4 million people dollars should be added to jobs in the industry during this period in the United States. The highest median annual salary was recorded at USD 214,000 or more for physicians and surgeons in 2020. Similarly, the median yearly salary recorded for other health professions in June 2019 was USD 172,380 for dentists, USD 149,370 for physicians, USD 97,147 for occupational therapists, and USD 31,413 for various health care support professions, such as home health aides and medical transcriptionists. According to statistics released by the United States Bureau of Labor Statistics, the employment rate of various health professionals in the health sector is expected to increase by 15% between 2024 and 2029. Increased demand for services and facilities Medical Healthcare in the North America region is estimated to significantly impact the North American Pap test and HPV test market growth in the area between 2024 and 2029.
Besides, the increase in spending on the population of countries like the United States and Canada further stimulates this industry's growth. Per capita purchasing power parity (PPP) -based health expenditure in the United States has increased significantly from $ 9,272.27 in 2018 to $ 10,235.18 in 2020, while it increased from USD 4,832.83 USD in 2018 to USD 5,151 in 2020 in Canada. According to the World Health Organization, spending on personal health care in the United States, reported by the Centers for Disease Control and Prevention, is expected to increase by a 4.8% annual percentage change in percentage over the period 2010-2020, with spending a total of $ 2.237 billion in 2010, which rose to 3.231 billion USD in 2020. It can be attributed to the high demand for new drugs.
MARKET SEGMENTATION
Some of the companies dominating the North America HPV Testing and PAP Test Market include
- Abbott Laboratories
- Qiagen N.V.
- Roche Diagnostics
- Hologic, Inc.
- Becton, Dickinson and Company
- Quest Diagnostics
- Onco Health Corporation
- Seegene, Inc.
- Femasys Inc.
- Arbor Vita Corporation
MARKET SEGMENTATION
This research report on the North America HPV Testing and Pap Test Market has been segmented and sub-segmented into the following categories:
By Test Type
- HPV Testing
- Follow-up HPV Testing
- HPV Primary Testing
- Co-Testing
- PAP Test
By Application
- Vaginal Cancer Screening
- Cervical Cancer Screening
By End-users
- Laboratories
- Hospitals
- Physicians
- Offices and Clinics
By Country
- The United States
- Canada
- Rest of North America